HB 5651 Summary

• Establishes the "Right to Try Act" allowing terminally ill patients to access investigational drugs, biological products, and devices that have completed FDA Phase 1 trials but lack final approval.

• Requires eligible patients to have exhausted all FDA-approved treatments, receive physician recommendation, and provide written informed consent that includes disclosure of potential risks, outcomes, and financial liability.

• Permits manufacturers to provide investigational treatments without compensation or to charge patients for manufacturing costs, with no requirement to make treatments available.

• Prohibits state licensing boards from disciplining health care providers solely for recommending experimental treatments to eligible patients, as long as recommendations meet medical standards of care.

• Shields manufacturers and care providers from private lawsuits for patient harm resulting from investigational treatments if they act in good faith compliance with the act and exercise reasonable care.